FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum
Increasing evidence shows that the early lesions of Parkinson's disease (PD) originate from gut, and correction of microbiota dysbiosis is a promising therapy for PD. FLZ is a neuroprotective agent on PD, which has been validated capable of alleviating microbiota dysbiosis in PD mice. However,...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221138352400412X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249542780321792 |
|---|---|
| author | Meiyu Shang Jingwen Ning Caixia Zang Jingwei Ma Yang Yang Yueqi Jiang Qiuzhu Chen Yirong Dong Jinrong Wang Fangfang Li Xiuqi Bao Dan Zhang |
| author_facet | Meiyu Shang Jingwen Ning Caixia Zang Jingwei Ma Yang Yang Yueqi Jiang Qiuzhu Chen Yirong Dong Jinrong Wang Fangfang Li Xiuqi Bao Dan Zhang |
| author_sort | Meiyu Shang |
| collection | DOAJ |
| description | Increasing evidence shows that the early lesions of Parkinson's disease (PD) originate from gut, and correction of microbiota dysbiosis is a promising therapy for PD. FLZ is a neuroprotective agent on PD, which has been validated capable of alleviating microbiota dysbiosis in PD mice. However, the detailed mechanisms still need elucidated. Through metabolomics and 16S rRNA analysis, we identified glycoursodeoxycholic acid (GUDCA) was the most affected differential microbial metabolite by FLZ treatment, which was specially and negatively regulated by Clostridium innocuum, a differential microbiota with the strongest correlation to GUDCA production, through inhibiting bile salt hydrolase (BSH) enzyme. The protection of GUDCA on colon and brain were also clarified in PD models, showing that it could activate Nrf2 pathway, further validating that FLZ protected dopaminergic neurons through promoting GUDCA production. Our study uncovered that FLZ improved PD through microbiota–gut–brain axis, and also gave insights into modulation of microbial metabolites may serve as an important strategy for treating PD. |
| format | Article |
| id | doaj-art-6781e1dae1694c6d80f8a9cd3fb9ead0 |
| institution | OA Journals |
| issn | 2211-3835 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj-art-6781e1dae1694c6d80f8a9cd3fb9ead02025-08-20T01:58:28ZengElsevierActa Pharmaceutica Sinica B2211-38352025-02-0115297399010.1016/j.apsb.2024.10.011FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuumMeiyu Shang0Jingwen Ning1Caixia Zang2Jingwei Ma3Yang Yang4Yueqi Jiang5Qiuzhu Chen6Yirong Dong7Jinrong Wang8Fangfang Li9Xiuqi Bao10Dan Zhang11State Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaCorresponding authors.; State Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaCorresponding authors.; State Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaIncreasing evidence shows that the early lesions of Parkinson's disease (PD) originate from gut, and correction of microbiota dysbiosis is a promising therapy for PD. FLZ is a neuroprotective agent on PD, which has been validated capable of alleviating microbiota dysbiosis in PD mice. However, the detailed mechanisms still need elucidated. Through metabolomics and 16S rRNA analysis, we identified glycoursodeoxycholic acid (GUDCA) was the most affected differential microbial metabolite by FLZ treatment, which was specially and negatively regulated by Clostridium innocuum, a differential microbiota with the strongest correlation to GUDCA production, through inhibiting bile salt hydrolase (BSH) enzyme. The protection of GUDCA on colon and brain were also clarified in PD models, showing that it could activate Nrf2 pathway, further validating that FLZ protected dopaminergic neurons through promoting GUDCA production. Our study uncovered that FLZ improved PD through microbiota–gut–brain axis, and also gave insights into modulation of microbial metabolites may serve as an important strategy for treating PD.http://www.sciencedirect.com/science/article/pii/S221138352400412XParkinson's diseaseFLZGlycoursodeoxycholic acidClostridium innocuumGut–brain axisMicrobiota dysbiosis |
| spellingShingle | Meiyu Shang Jingwen Ning Caixia Zang Jingwei Ma Yang Yang Yueqi Jiang Qiuzhu Chen Yirong Dong Jinrong Wang Fangfang Li Xiuqi Bao Dan Zhang FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum Acta Pharmaceutica Sinica B Parkinson's disease FLZ Glycoursodeoxycholic acid Clostridium innocuum Gut–brain axis Microbiota dysbiosis |
| title | FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum |
| title_full | FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum |
| title_fullStr | FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum |
| title_full_unstemmed | FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum |
| title_short | FLZ attenuates Parkinson's disease pathological damage by increasing glycoursodeoxycholic acid production via down-regulating Clostridium innocuum |
| title_sort | flz attenuates parkinson s disease pathological damage by increasing glycoursodeoxycholic acid production via down regulating clostridium innocuum |
| topic | Parkinson's disease FLZ Glycoursodeoxycholic acid Clostridium innocuum Gut–brain axis Microbiota dysbiosis |
| url | http://www.sciencedirect.com/science/article/pii/S221138352400412X |
| work_keys_str_mv | AT meiyushang flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT jingwenning flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT caixiazang flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT jingweima flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT yangyang flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT yueqijiang flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT qiuzhuchen flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT yirongdong flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT jinrongwang flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT fangfangli flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT xiuqibao flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum AT danzhang flzattenuatesparkinsonsdiseasepathologicaldamagebyincreasingglycoursodeoxycholicacidproductionviadownregulatingclostridiuminnocuum |